

Stanley Satz Biography

Stanley Satz, Ph.D. is Chairman, Chief Scientific Officer and co-founder of Bio-Nucleonics, Inc. a Miami, Florida based manufacturer of diagnostic and therapeutic radiopharmaceuticals, nanoengineered molecular imaging agents and medical devices. A former educator, Satz comes from the 'death sciences' to the 'life sciences'. He is a scientist and radiation physicist with more than 25 years of research and development and production experience, manufacturing and marketing of products for medical and industrial use. In addition, Satz is Chairman of the G8 International Working Group on Nanosafety and Nanosecurity, headquartered in Como, Italy.

He is a leading authority on the development of radiopharmaceuticals required for effective targeted gene therapy, stem cell therapy, radiation therapy and imaging chemistry. His studies have led to initiation of multiple small molecule clinical trials. Basic coordination chemistry studies have also addressed the synthesis and in vivo validation of novel agents that have been translated from pre-clinical studies to clinical use onwards to commercial products for both imaging and therapy of cancer and rare diseases including amino acid dehydrocarbolase deficiency, neuroblastoma, acute lymphoblastic leukemia and diffuse intrinsic pontine glioma.

Satz founded Bio-Nucleonics after leaving Mount Sinai Medical Center of Miami Beach and a Professorship the University of Miami. A graduate of the University of Miami, he is former Chairman and of the Scientific Advisory Board of Florida Atlantic University, and is on the Board of the U.S. Industry Coalition, and a publicly traded biotechnology company. He developed a U.S. Food and Drug Administration approved therapeutic radiopharmaceutical Strontium Chloride Sr-89 Injection, for treatment of bone pain arising from metastatic prostate and breast cancer, and TheraностTM, a nanoparticle engineered drug for peptide receptor radionuclide targeted therapy of cancerous tumors, currently in clinical trials. Satz has authored numerous journal articles and holds five issued and three pending medically related U.S. patents.

Satz concentrates his scientific and technical leadership on radiopharmaceutical and receptor-avid peptide development and strategic planning. He is also co-founder of Boca Raton, Florida-based Advanced Imaging Projects, Inc. (AiP), a clinical stage specialty biopharmaceutical company focused on the discovery, development and commercialization of molecular medicines for prevention, diagnosis and treatment of oncological, neurological and infectious disorders; childhood rare diseases in particular. AiP GmbH, located near Erfurt, Germany was established in 2017. In the Company's product portfolio are small molecules that demonstrate safety and efficacy in clinical management of neuroblastoma. Pediatric rare disease designations were granted by the FDA for multiple indications including aromatic-L amino acid decarboxylase deficiency neuroblastoma, diffuse intrinsic pontine glioma and acute lymphoblastic leukemia.